ArticlemBio2018
Synergistic Lethality of a Binary Inhibitor of Mycobacterium tuberculosis KasA.
Open access · goldAbstract read
In one paragraph
Article in mBio, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 49 citations in OpenAlex.
- Targeting Mycolic Acid Biosynthesis with Cyclic Sulfamates: A New Strategy againstACS infectious diseases · 2025Article
- Mycobacterium tuberculosis FAS-II pathway targeted integrative deep learning based identification of potential anti-tubercular agents.Journal of computer-aided molecular design · 2025Article
- Review
- Target Identification in Anti-Tuberculosis Drug Discovery.International journal of molecular sciences · 2023Review
- Emerging Extracellular Molecular Targets for Innovative Pharmacological Approaches to Resistant Mtb Infection.Biomolecules · 2023Review
- Review
- A Review of Fatty Acid Biosynthesis Enzyme Inhibitors as Promising Antimicrobial Drugs.Pharmaceuticals (Basel, Switzerland) · 2023Review
- 1,3-Diarylpyrazolyl-acylsulfonamides Target HadAB/BC Complex inACS infectious diseases · 2022Article
- CRISPRi chemical genetics and comparative genomics identify genes mediating drug potency in Mycobacterium tuberculosis.Nature microbiology · 2022Article
- Machine Learning Models forMolecular pharmaceutics · 2022Article
- Review
- Indole: A promising scaffold for the discovery and development of potential anti-tubercular agents.Current research in pharmacology and drug discovery · 2022Review
- Unraveling the mechanisms of intrinsic drug resistance inFrontiers in cellular and infection microbiology · 2022Review
- An Outline of the Latest Crystallographic Studies on Inhibitor-Enzyme Complexes for the Design and Development of New Therapeutics against Tuberculosis.Molecules (Basel, Switzerland) · 2021Review
- Ligand-protein interactions of plant-isolated (9z,12z)-octadeca-9,12-dienoic acid with Β-ketoacyl-Acp synthase (KasA) in potential anti-tubercular drug designing.Scientific African · 2021Article
- Structure-Activity Relationships of Pyrazolo[1,5-ACS infectious diseases · 2021Article
- Tuberculosis Drug Discovery: A Decade of Hit Assessment for Defined Targets.Frontiers in cellular and infection microbiology · 2021Review
- Lack of Specificity of Phenotypic Screens for Inhibitors of the Mycobacterium tuberculosis FAS-II System.Antimicrobial agents and chemotherapy · 2020Article
- Computational Approaches to Identify Molecules Binding toACS omega · 2020Article
- Developing New Drugs for Mycobacterium tuberculosis Therapy: What Information Do We Get from Preclinical Animal Models?Antimicrobial agents and chemotherapy · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors at 4 institutions in 1 country.
Pradeep Kumar *Division of Infectious Disease, Department of Medicine, and the Ruy V. Lourenco Center for the Study of Emerging and Reemerging Pathogens, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, New Jersey, USA.
Glenn C Capodagli *Department of Microbiology, Biochemistry and Molecular Genetics, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, USA.
Divya Awasthi *Department of Pharmacology, Physiology & Neuroscience, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, New Jersey, USA.
Riju ShresthaDivision of Infectious Disease, Department of Medicine, and the Ruy V. Lourenco Center for the Study of Emerging and Reemerging Pathogens, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, New Jersey, USA.
Karishma MaharajaDepartment of Microbiology, Biochemistry and Molecular Genetics, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, USA.
Paridhi SukhejaDivision of Infectious Disease, Department of Medicine, and the Ruy V. Lourenco Center for the Study of Emerging and Reemerging Pathogens, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, New Jersey, USA.
Shao-Gang LiDepartment of Pharmacology, Physiology & Neuroscience, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, New Jersey, USA.
Daigo InoyamaDepartment of Pharmacology, Physiology & Neuroscience, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, New Jersey, USA.
Matthew ZimmermanPublic Health Research Institute, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, New Jersey, USA.
Hsin Pin Ho LiangPublic Health Research Institute, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, New Jersey, USA.
Jansy SarathyPublic Health Research Institute, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, New Jersey, USA.
Marizel MinaPublic Health Research Institute, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, New Jersey, USA.
George RasicPublic Health Research Institute, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, New Jersey, USA.
Riccardo RussoDivision of Infectious Disease, Department of Medicine, and the Ruy V. Lourenco Center for the Study of Emerging and Reemerging Pathogens, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, New Jersey, USA.
Alexander L PerrymanDepartment of Pharmacology, Physiology & Neuroscience, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, New Jersey, USA.
Todd RichmannDivision of Infectious Disease, Department of Medicine, and the Ruy V. Lourenco Center for the Study of Emerging and Reemerging Pathogens, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, New Jersey, USA.
Aditi GuptaDivision of Infectious Disease, Department of Medicine, and the Ruy V. Lourenco Center for the Study of Emerging and Reemerging Pathogens, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, New Jersey, USA.
Eric SingletonDivision of Infectious Disease, Department of Medicine, and the Ruy V. Lourenco Center for the Study of Emerging and Reemerging Pathogens, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, New Jersey, USA.
Sheetal VermaDivision of Infectious Disease, Department of Medicine, and the Ruy V. Lourenco Center for the Study of Emerging and Reemerging Pathogens, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, New Jersey, USA.
Seema HusainDepartment of Microbiology, Biochemistry and Molecular Genetics, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, USA.
Patricia SoteropoulosDepartment of Microbiology, Biochemistry and Molecular Genetics, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, USA.
Zhe WangDivision of Infectious Diseases, Department of Medicine, Weill Cornell Medical College, New York, New York, USA.
Roxanne MorrisDivision of Infectious Diseases, Department of Medicine, Weill Cornell Medical College, New York, New York, USA.
Gene PorterWuXi AppTec, Plainsboro, New Jersey, USA.
Gautam AgnihotriWuXi AppTec, Plainsboro, New Jersey, USA.
Padmini SalgameDivision of Infectious Disease, Department of Medicine, and the Ruy V. Lourenco Center for the Study of Emerging and Reemerging Pathogens, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, New Jersey, USA.
Sean EkinsCollaborations Pharmaceuticals, Inc., Raleigh, North Carolina, USA.
Kyu Y RheeDivision of Infectious Diseases, Department of Medicine, Weill Cornell Medical College, New York, New York, USA.
Nancy ConnellDivision of Infectious Disease, Department of Medicine, and the Ruy V. Lourenco Center for the Study of Emerging and Reemerging Pathogens, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, New Jersey, USA.
Véronique DartoisPublic Health Research Institute, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, New Jersey, USA.
Matthew B Neiditch *Department of Microbiology, Biochemistry and Molecular Genetics, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, USA matthew.neiditch@njms.rutgers.edu freundjs@rutgers.edu allandda@njms.rutgers.edu.
Joel S Freundlich *Division of Infectious Disease, Department of Medicine, and the Ruy V. Lourenco Center for the Study of Emerging and Reemerging Pathogens, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, New Jersey, USA matthew.neiditch@njms.rutgers.edu freundjs@rutgers.edu allandda@njms.rutgers.edu.
David Alland *Division of Infectious Disease, Department of Medicine, and the Ruy V. Lourenco Center for the Study of Emerging and Reemerging Pathogens, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, New Jersey, USA matthew.neiditch@njms.rutgers.edu freundjs@rutgers.edu allandda@njms.rutgers.edu.
Rutgers, The State University of New Jersey · USCornell University · USWuXi AppTec (United States) · USCollaborations Pharmaceuticals (United States) · US
Funding
Therapeutics for drug resistant-bacteria: Arylpropionyl-phloroglucinolsU19AI109713 · NIAID · RBHS-NEW JERSEY MEDICAL SCHOOL · PI FREUNDLICH, JOEL STEPHEN · 2014 to 2018
$26.9MPREDOCTORAL TRAINING PROGRAM IN MICROBIAL PATHOGENESIST32AI007640 · NIAID · YALE UNIVERSITY · PI GOODMAN, ANDREW L · 2000 to 2022
$4.3MA QTRAP 6500 LC-MS/MS System from SCIEX for high accuracy drug content analysisS10OD023524 · OD · RBHS-NEW JERSEY MEDICAL SCHOOL · PI DARTOIS, VERONIQUE · 2017 to 2017
$526kDiscovery and validation of drug targets in vulnerable pathways of MtbR21AI111647 · NIAID · RBHS-NEW JERSEY MEDICAL SCHOOL · PI ALLAND, DAVID · 2014 to 2015
$437kStructure-guided optimization of an in vivo active small molecule antitubercular targeting KasAR41AI134561 · NIAID · COLLABORATIONS PHARMACEUTICALS, INC. · PI EKINS, SEAN, FREUNDLICH, JOEL STEPHEN · 2018 to 2018
$225kNIAID NIH HHS R21 AI111647NIAID NIH HHS R41 AI134561NIAID NIH HHS T32 AI007640NIAID NIH HHS U19 AI109713NIH HHS S10 OD023524
Abstract
We report GSK3011724A (DG167) as a binary inhibitor of β-ketoacyl-ACP synthase (KasA) in
Indexed as
Drug Synergism3-Oxoacyl-(Acyl-Carrier-Protein) SynthaseAnimalsAntitubercular AgentsCell LineCrystallographyDrug DiscoveryFemaleGene Expression ProfilingIsoniazidMiceMice, Inbred BALB CModels, MolecularMolecular ChaperonesMycobacterium tuberculosisOxidoreductases3-Oxoacyl-(Acyl-Carrier-Protein) SynthaseAntitubercular AgentsIsoniazidMolecular ChaperonesOxidoreductasesantitubercularDG167drug developmentisoniazidKasAMycobacterium tuberculosismycolic acid biosynthesissynergistic lethality
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.